Abstract: A human oral at least partly enteric formulation comprising one or more jojoba components, for controlling, stimulating or modulating functions for patients suffering from a degenerative disease, or for patients at risk from suffering from a degenerative disease, or for patients under therapeutic treatment of a degenerative disease.

Abstract: A human oral at least partly enteric formulation comprising one or more jojoba components, for controlling, stimulating or modulating functions for patients suffering from a degenerative disease, or for patients at risk from suffering from a degenerative disease, or for patients under therapeutic treatment of a degenerative disease.

Abstract: Methods of inhibiting angiogenesis in humans and animals by administering a effective amount of a secondary plant metabolite from jojoba, having the general formula I shown below, are disclosed. Preferred compounds having general formula I include 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4,5-dimethylsimmondsin, 4-desmethylsimmondsin-2?-ferulate, 5-desmethylsimmondsin-2?-ferulate, 4,5-didesmethylsimmondsin-2?-ferulate and 4,5-dimethylsimmondsin-2?-ferulate. Such compounds can be synthesized chemically according to well known techniques or can be isolated from refined and de-oiled jojoba flour by conventional extraction techniques using polar solvents such as a ketone or a low boiling point alcohol.

Abstract: The present invention relates to the use of an active component derived from jojoba, and in particular a simmondsin, steroisomeric forms, racemic mixtures, metabolites, pharmaceutically acceptable esters or salts thereof, or mixtures thereof for the manufacture of a medicament for inhibiting angiogenesis and for the manufacture of a medicament for treating angiogenesis-related disease. The present invention further relates to pharmaceutical compositions for inhibiting angiogenesis or for treating angiogenesis-related diseases in humans or animals and to methods for inhibiting angiogenesis and for treating angiogenesis-related diseases in humans or animals.